H Butzkueven
Overview
Explore the profile of H Butzkueven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
van der Walt A, Stankovich J, Bahlo M, Taylor B, van der Mei I, Foote S, et al.
Mult Scler
. 2010 Dec;
17(3):344-52.
PMID: 21149397
Background: HLA-DRB1*1501 (DR15) and other HLA class II alleles increase the risk of developing multiple sclerosis (MS). However, the contribution of genetic heterogeneity to the clinical course of MS remains...
22.
Shaw C, Chapman C, Butzkueven H
Intern Med J
. 2009 Oct;
39(12):792-9.
PMID: 19817917
The task of confirming a diagnosis of multiple sclerosis (MS), one of the commonest neurological disorders affecting young adults, has altered significantly in the magnetic resonance imaging era. Conversely, key...
23.
Van der Walt A, Stankovich J, Bahlo M, Taylor B, van der Mei I, Foote S, et al.
Neurology
. 2009 Sep;
73(13):1018-25.
PMID: 19786693
Background: The influence of APOE allelic heterogeneity on multiple sclerosis (MS) disease severity has been reported in multiple datasets with conflicting results. Several studies have reported an unfavorable association of...
24.
Stankovich J, Butzkueven H, Marriott M, Chapman C, Tubridy N, Tait B, et al.
Tissue Antigens
. 2009 Apr;
74(1):17-21.
PMID: 19392788
Human leucocyte antigen (HLA)-DRB1*1501 and other class II alleles influence susceptibility to multiple sclerosis (MS), but their contribution if any to the clinical course of MS remains uncertain. Here, we...
25.
Haartsen J, Marriott M, Butzkueven H
Mult Scler
. 2009 Mar;
15(4):520.
PMID: 19324983
No abstract available.
26.
Rubio J, Stankovich J, Field J, Tubridy N, Marriott M, Chapman C, et al.
Genes Immun
. 2008 Jul;
9(7):624-30.
PMID: 18650830
A recent genome-wide association study (GWAS) conducted by the International Multiple Sclerosis Genetics Consortium (IMSGC) identified a number of putative MS susceptibility genes. Here we have performed a replication study...
27.
Butzkueven H, Kolbe S, Jolley D, Brown J, Cook M, van der Mei I, et al.
J Clin Neurosci
. 2007 Dec;
15(2):130-7.
PMID: 18068987
Linear measures of cerebral ventricular enlargement may act as surrogate measures of cerebral atrophy in multiple sclerosis (MS). Linear atrophy markers were measured from routine MRI scans during a population...
28.
Burfoot R, Jensen C, Field J, Stankovich J, Varney M, Johnson L, et al.
Tissue Antigens
. 2007 Nov;
71(1):42-50.
PMID: 17971048
This study is an extension to previously published work that has linked variation in the human leukocyte antigen (HLA) class I region with susceptibility to multiple sclerosis (MS) in Australians...
29.
van der Mei I, Ponsonby A, Dwyer T, Blizzard L, Taylor B, Kilpatrick T, et al.
J Neurol
. 2007 Apr;
254(5):581-90.
PMID: 17426912
Background: Adequate 25(OH)D levels are required to prevent adverse effects on bone health. Population-based data on factors associated with 25(OH)D levels of people with MS have been lacking. Objectives: To...
30.
Butzkueven H, Chapman J, Cristiano E, GrandMaison F, Hoffmann M, Izquierdo G, et al.
Mult Scler
. 2007 Feb;
12(6):769-74.
PMID: 17263005
Observational cohort studies are a powerful tool to assess the long-term outcome in chronic diseases. This study design has been utilized in local and regional outcome studies in multiple sclerosis...